Cyteir Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.39 Insider Own11.70% Shs Outstand35.33M Perf Week4.60%
Market Cap56.69M Forward P/E- EPS next Y-1.67 Insider Trans0.55% Shs Float31.35M Perf Month15.20%
Income-49.10M PEG- EPS next Q-0.34 Inst Own69.80% Short Float / Ratio0.74% / 2.29 Perf Quarter-2.57%
Sales- P/S- EPS this Y-98.00% Inst Trans-4.19% Short Interest0.23M Perf Half Y-36.38%
Book/sh4.36 P/B0.39 EPS next Y-33.80% ROA-27.40% Target Price3.67 Perf Year-71.86%
Cash/sh4.63 P/C0.37 EPS next 5Y42.90% ROE-28.90% 52W Range1.13 - 7.31 Perf YTD3.33%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-76.68% Beta-
Dividend %- Quick Ratio27.10 Sales past 5Y- Gross Margin- 52W Low50.88% ATR0.15
Employees40 Current Ratio27.10 Sales Q/Q- Oper. Margin- RSI (14)57.14 Volatility7.09% 10.65%
OptionableNo Debt/Eq0.00 EPS Q/Q6.30% Profit Margin- Rel Volume0.49 Prev Close1.59
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume101.46K Price1.71
Recom1.70 SMA205.64% SMA5014.88% SMA200-20.53% Volume49,439 Change7.23%
Feb-07-22Initiated Northland Capital Outperform $16
Jul-13-21Initiated Wedbush Outperform $40
Jul-13-21Initiated Morgan Stanley Overweight $33
Jul-13-21Initiated JP Morgan Overweight $30
Jul-13-21Initiated BofA Securities Buy $23
Jan-19-23 04:30PM
Nov-07-22 04:01PM
Oct-22-22 08:34AM
Oct-12-22 08:00AM
Aug-31-22 07:30AM
06:13AM Loading…
Aug-24-22 06:13AM
Aug-11-22 10:55AM
Aug-08-22 04:01PM
Aug-01-22 08:00AM
Jun-05-22 08:30AM
May-31-22 08:00AM
May-15-22 08:12AM
May-05-22 04:30PM
May-04-22 08:00AM
May-03-22 09:00AM
09:00AM Loading…
Apr-25-22 09:00AM
Apr-18-22 07:30AM
Mar-17-22 06:49AM
Mar-16-22 04:01PM
Mar-09-22 05:06PM
Feb-24-22 04:30PM
Feb-10-22 11:51AM
Feb-08-22 07:30AM
Feb-07-22 07:30AM
Jan-12-22 07:30AM
Jan-03-22 07:30AM
Dec-16-21 07:30AM
Nov-12-21 07:30AM
Nov-01-21 07:30AM
Sep-20-21 07:30AM
09:01AM Loading…
Sep-18-21 09:01AM
Sep-14-21 07:00AM
Sep-01-21 07:30AM
Aug-09-21 04:05PM
Aug-02-21 07:30AM
Jun-22-21 05:00PM
Jun-17-21 07:15PM
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RENSCHLER MARKUS MDPresident and CEODec 21Option Exercise1.07136,782146,060978,736Dec 23 04:47 PM
Zakrzewski Joseph SDirectorDec 07Buy1.3021,20227,563154,618Dec 08 05:09 PM
Novo Holdings A/S10% OwnerJul 20Sale3.00900,0002,700,0003,940,413Jul 22 06:52 PM
Zakrzewski Joseph SDirectorMay 12Buy1.617431,196133,416May 16 04:24 PM
Zakrzewski Joseph SDirectorMay 11Buy1.701,0001,700132,673May 12 04:35 PM
THERO JOHN FDirectorMay 10Buy2.0010,00020,00010,000May 12 04:38 PM
Zakrzewski Joseph SDirectorMay 10Buy1.8949,40693,377131,673May 12 04:35 PM